UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers

JAMA : the journal of the American Medical Association, 2021-05, Vol.325 (19), p.2015

2021

Volltextzugriff (PDF)

Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma

Nature communications, 2021-07, Vol.12 (1), p.4127-4127, Article 4127

2021

Volltextzugriff (PDF)

Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential

Frontiers in immunology, 2021-07, Vol.12, p.682492-682492

2021

Volltextzugriff (PDF)

Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Cancers, 2021-06, Vol.13 (13), p.3116

2021

Volltextzugriff (PDF)

Correction: Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations

PloS one, 2024-05, Vol.19 (5), p.e0304890

2024

Volltextzugriff (PDF)

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

Journal of translational medicine, 2022-09, Vol.20 (1), p.1-419, Article 419

2022

Volltextzugriff (PDF)

An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses

PloS one, 2021-09, Vol.16 (9), p.e0258041-e0258041

2021

Volltextzugriff (PDF)

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer

BMC cancer, 2023-06, Vol.23 (1), p.605-605, Article 605

2023

Volltextzugriff (PDF)

Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations

PloS one, 2021-07, Vol.16 (7), p.e0253178

2021

Volltextzugriff (PDF)

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

Journal for immunotherapy of cancer, 2022-05, Vol.10 (5), p.e004345

2022

Volltextzugriff (PDF)

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

Oncoimmunology, 2020-01, Vol.9 (1), p.1730538-1730538

2020

Volltextzugriff (PDF)

Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference?

Expert opinion on biological therapy, 2023-02, Vol.23 (2), p.115-117

Mangsbo, Sara M

2023

Volltextzugriff (PDF)

AdCD40L Immunogene Therapy for Bladder Carcinoma— The First Phase I/IIa Trial

Clinical cancer research, 2010-06, Vol.16 (12), p.3279-3287

2010

Volltextzugriff (PDF)

Tumor-Specific Bacteriophages Induce Tumor Destruction through Activation of Tumor-Associated Macrophages

The Journal of immunology (1950), 2009-03, Vol.182 (5), p.3105-3111

2009

Volltextzugriff (PDF)

Circulating specific antibodies enhance systemic cross‐priming by delivery of complexed antigen to dendritic cells in vivo

European journal of immunology, 2012-03, Vol.42 (3), p.598-606

2012

Volltextzugriff (PDF)

Local checkpoint inhibition of CTLA‐4 as a monotherapy or in combination with anti‐PD1 prevents the growth of murine bladder cancer

European journal of immunology, 2017-02, Vol.47 (2), p.385-393

2017

Volltextzugriff (PDF)

Complement Activation by CpG in a Human Whole Blood Loop System: Mechanisms and Immunomodulatory Effects

The Journal of immunology (1950), 2009-11, Vol.183 (10), p.6724-6732

2009

Volltextzugriff (PDF)

Epitopes Displayed in a Cyclic Peptide Scaffold Bind SARS‐COV‐2 Antibodies

Chembiochem : a European journal of chemical biology, 2023-08, Vol.24 (15), p.e202300103-n/a

2023

Volltextzugriff (PDF)

Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment

Oncotarget, 2016-07, Vol.7 (31), p.50277-50289

2016

Volltextzugriff (PDF)

Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model

International immunopharmacology, 2024-01, Vol.126, p.111225-111225, Article 111225

2024

Volltextzugriff (PDF)

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

Journal of immunotherapy, 2010-04, Vol.33 (3), p.225-235

2010

Volltextzugriff (PDF)

The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity

Clinical cancer research, 2015-03, Vol.21 (5), p.1115-1126

2015

Volltextzugriff (PDF)

MALT1 inhibition suppresses antigen-specific T cell responses

Cellular immunology, 2024-03, Vol.397-398, p.104814-104814, Article 104814

2024

Volltextzugriff (PDF)

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

Cancer Immunology and Immunotherapy, 2017-01, Vol.66 (1), p.1-7

2017

Volltextzugriff (PDF)

Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer

Cancer immunology research, 2014, Vol.2 (1), p.80-90

2014

Volltextzugriff (PDF)

1 – 25 von 71

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(66)

Publikationsform

Artikel
(71)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(57)
Life Sciences & Biomedicine
(51)
Immunology
(33)
Immunotherapy
(24)
Medicin Och Hälsovetenskap
(23)
Oncology
(21)
Humans
(20)
Animals
(18)
Female
(18)
Male
(18)
Mice
(17)
Antibodies
(15)
Immune Response
(13)
Mice, Inbred C57bl
(13)
Lymphocytes T
(12)
Lymphocytes
(11)
Bladder Cancer
(10)
Cell Line, Tumor
(10)
Covid-19
(10)
Severe Acute Respiratory Syndrome Coronavirus 2
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers

Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma

Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential

Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade

Correction: Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses

Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer

Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations

Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy

Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference?

AdCD40L Immunogene Therapy for Bladder Carcinoma— The First Phase I/IIa Trial

Tumor-Specific Bacteriophages Induce Tumor Destruction through Activation of Tumor-Associated Macrophages

Circulating specific antibodies enhance systemic cross‐priming by delivery of complexed antigen to dendritic cells in vivo

Local checkpoint inhibition of CTLA‐4 as a monotherapy or in combination with anti‐PD1 prevents the growth of murine bladder cancer

Complement Activation by CpG in a Human Whole Blood Loop System: Mechanisms and Immunomodulatory Effects

Epitopes Displayed in a Cyclic Peptide Scaffold Bind SARS‐COV‐2 Antibodies

Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment

Bridging responses to a human telomerase reverse transcriptase-based peptide cancer vaccine candidate in a mechanism-based model

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity

MALT1 inhibition suppresses antigen-specific T cell responses

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation

Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer

Suchergebnisse filtern